AGLE Insider Trading Activity and SEC Form 4 Filings
AGLE insider trading summary
No open-market insider purchases or sales of Aeglea BioTherapeutics, Inc. (AGLE) have been reported on SEC Form 4 in the past 12 months.
Latest AGLE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 25, 2022 | Marcio Souza | Director | Buy | $50K (90,000 @ $0.56) |
| Jun 8, 2022 | Michael Conick Hanley Jr. | Chief Commercial Officer | Buy | $20K (28,200 @ $0.71) |
| Mar 16, 2022 | Anthony G. Quinn | President & CEO | Buy | $188K (80,079 @ $2.34) |
| Mar 15, 2022 | Anthony G. Quinn | President & CEO | Buy | $79K (42,417 @ $1.86) |
| Mar 14, 2022 | Anthony G. Quinn | President & CEO | Buy | $130K (67,472 @ $1.93) |
| Mar 11, 2022 | Jonathan Alspaugh | Chief Financial Officer | Buy | $156K (75,000 @ $2.08) |
| Mar 11, 2022 | Anthony G. Quinn | President & CEO | Buy | $72K (34,777 @ $2.06) |
| Dec 13, 2021 | Armen Shanafelt | Director | Buy | $54K (14,685 @ $3.65) |
| Dec 10, 2021 | Anthony G. Quinn | President & CEO | Buy | $39K (10,526 @ $3.75) |
| Dec 10, 2021 | Armen Shanafelt | Director | Buy | $49K (13,516 @ $3.65) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.